Federal grants to Afasci, Inc.
Afasci, Inc. in Burlingame, California received $4.4 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Drug Use and Addiction Research Programs, with $3.3 million. In fiscal 2025 it was awarded $50,000.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$4.4 million
- Awards4
- Awarded in FY 2025$50,000
- Largest award$3.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 0 | $0 |
| FY 2023 | 3 | $2.3 million |
| FY 2024 | 2 | $2.0 million |
| FY 2025 | 1 | $50,000 |
Programs that fund Afasci, Inc.
| Program | Awards | Amount |
|---|---|---|
| Drug Use and Addiction Research Programs | 2 | $3.3 million |
| Alcohol Research Programs | 1 | $982,702 |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 1 | $50,000 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $4.4 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Clinical phase i trials on an ind single molecule dual inhibitor of CAV3 channels and soluble epoxide hydrolase for treatment of neuropathic pain - 7. Project summary we propose conducting clinical phase i trials on an active ind (157314), AFA-281, a non-opioid, single small molecule that inhibits b | Drug Use and Addiction Research Programs | September 21, 2023 | $3.0 million |
| Development of a novel medication for alcohol use disorder with an active ind dual inhibitor of t-type calcium channel and soluble epoxide hydrolase - 7. Summary alcohol use disorder (AUD) is the most prevalent substance use disorder worldwide and often co-occurs with chronic pain, anxiety, depressi | Alcohol Research Programs | September 22, 2023 | $982,702 |
| Developing a novel treatment of cocaine use disorder using an ind dual inhibitor of CAV3 channel and soluble epoxide hydrolase - 7. Project summary our sbir phase i proposal focuses on preclinical proof of concept studies on our ind AFA-281 for treatment cocaine use disorder (CUD). AFA-281 is a new | Drug Use and Addiction Research Programs | September 7, 2023 | $319,547 |
| Clinical phase i trials on an ind single molecule dual inhibitor of CAV3 channels and soluble epoxide hydrolase for treatment of neuropathic pain - 7. Project summary we propose conducting clinical phase i trials on an active ind (157314), AFA-281, a non-opioid, single small molecule that inhibits b | Extramural Research Programs in the Neurosciences and Neurological Disorders | September 7, 2023 | $50,000 |
Questions people ask
How much federal grant money does Afasci, Inc. get?
$4.4 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Afasci, Inc. the most?
The Department of Health and Human Services, with $4.4 million in 4 awards.
What is Afasci, Inc.'s largest federal grant?
$3.0 million under Drug Use and Addiction Research Programs, with its first action in the period on September 21, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Afasci, Inc.?
Its largest are Drug Use and Addiction Research Programs, Alcohol Research Programs and Extramural Research Programs in the Neurosciences and Neurological Disorders.
Other grant recipients in Burlingame
- Magnus Medical Inc
- Central County Fire Department
- Collaborative Drug Discovery, Inc.
- The Sphere Institute
- Glint Photonics, Inc.
- City of Burlingame
- Nextrast, Inc
- The Junior State of America Foundation
Largest federal grant recipients in California · Federal grants in California